Our COPD patient group was in a clinically stable phase of the disease, where the main inflammatory process occurs in the lung microenvironment, and Tregs FoxP3 are involved in controlling pulmonary inflammation by stopping immune responses.[34] This phenomenon may explain our observation. The gene discussed is FOXP3; the disease is chronic obstructive pulmonary disease.